DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
The firm – which has teams in Beijing, Silicon Valley and Tokyo – closed its ninth flagship vehicle at $780 million. A filing dated May 2018 indicates a target of $750 million. A further $100 million...
Semiconductors are a popular investment target in China on the back of US decoupling and a push for self-sufficiency. Alex Banh, a managing partner of sector specialist IPV Capital, shares his views
China has imposed severe restrictions on private tutoring that appear to undermine the commercial viability of companies in the space, potentially making private equity investment unviable.
Best & Less Group (BLG), an Australian baby, kids and womenswear retailer, has raised A$60 million ($44 million) through a domestic IPO, facilitating a partial exit for majority owner Allegro Funds Group.
TransThera, a China-based drug developer, has raised $100 million in Series D funding led by CPE and China Structural Reform Fund.